Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CEL-SCI Corp CVM

Healthcare Biotechnology
CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system. The Company is focused on the development of product candidates and technologies, such as Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck... see more

Recent & Breaking News (NYSEAM:CVM)

CEL-SCI Achieves Milestone in July with Total of 232 Patients Enrolled to Date in Its Phase III Head and Neck Cancer Trial

Business Wire August 1, 2014

France Becomes 17th Country to Clear CEL-SCI for Patient Enrollment in Its Global Phase III Head and Neck Cancer Trial

Business Wire July 30, 2014

CEL-SCI Has Been Cleared to Begin Patient Enrollment

GlobeNewswire July 23, 2014

CEL-SCI Receives Regulatory Clearance to Expand Phase III Head and Neck Cancer Trial into Turkey

Business Wire July 22, 2014

CEL-SCI Expands Its Phase III Head and Neck Cancer Trial into Sri Lanka

Business Wire July 17, 2014

CEL-SCI Receives $225,000 NIH Research Grant to Develop Rheumatoid Arthritis Treatment

Business Wire July 15, 2014

CEL-SCI Presents Rheumatoid Arthritis Data at the 12th Vaccines Research & Development: All Things Considered Conference

Business Wire July 11, 2014

CEL-SCI Receives Regulatory Clearance to Expand CEL-SCI'S Phase III Head and Neck Cancer Trial into Austria

Business Wire July 8, 2014

CEL-SCI Reports 93% Increase in Sequential Quarterly Patient Enrollment in Its Phase III Head and Neck Cancer Trial

Business Wire July 1, 2014

CEL-SCI to Present at the 2014 BIO International Convention

Business Wire June 18, 2014

CEL-SCI Reports Continued Increase in Sequential Quarterly Patient Enrollment in Its Phase III Head and Neck Cancer Trial

Business Wire June 3, 2014

CEL-SCI Receives Approval to Expand Its Immunotherapy Phase III Head and Neck Cancer Trial into the United Kingdom

Business Wire June 2, 2014

University of Cincinnati Cancer Institute's Comprehensive Head and Neck Cancer Center Joins CEL-SCI'S Phase III Trial

Business Wire May 27, 2014

Three biotechs stocks with positive institutional transactions, good price to cash ratios and "buy" recommendations from street analysts

Accesswire May 22, 2014

CEL-SCI Corporation Reports Second Quarter Fiscal 2014 Financial Results

Business Wire May 13, 2014

CEL-SCI Reports April 2014 is Another Record Month for Patient Enrollment in Its Phase III Head and Neck Cancer Trial

Business Wire May 1, 2014

CEL-SCI Corporation Receives $3 Million from Warrant Exercises

Business Wire April 29, 2014

Southern Illinois University School of Medicine Becomes Clinical Site for CEL-SCI's Global Phase III Immunotherapy Head and Neck Cancer Trial

Business Wire April 28, 2014

CEL-SCI to Sponsor Symposium on Multikine at European Congress on Head & Neck Oncology 2014

Business Wire April 22, 2014

CEL-SCI Corporation Announces Closing of Public Offering for Gross Proceeds of $10 Million

Business Wire April 17, 2014